Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors

MIAMI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced that Pawel Kalinski, MD, vice chairman for translational...
January 23, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.

ORLANDO, Fla., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today commented on the overall market opportunity for its...
January 17, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility

ORLANDO, Fla., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today said it has entered into a sale and leaseback agreement for...
January 11, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Enhances Manufacturing Efficiency of Ampligen

ORLANDO, Fla., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), has successfully tested a new chemical catalyst used in the manufacturing process of Ampligen®, a...
January 09, 2018 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Presentation of New-Found Properties of Ampligen at Immuno-Oncology Frontiers Conference, Jan 24

ORLANDO, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today announced that Pawel Kalinski, MD, PhD, Rustum Family Professor...
January 02, 2018 10:08 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV

ORLANDO, Fla., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Orlando, FL, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D.,...
December 29, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. to Present at Biotech Showcase™ 2018

ORLANDO, Fla., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB), focused on pharmaceutical research, today announced, that it will be presenting at the Biotech Showcase™...
December 20, 2017 09:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer

NEW BRUNSWICK, N.J., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American:HEB) said, its Contract Manufacturing Organization (CMO) for Ampligen® has completed a commercial scale...
December 19, 2017 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Highlights Year-To-Date Progress, Outlines Key Objectives

Letter to Shareholders Posted on Website Revenue Up, Burn Rate Down Dramatically; Progress Cited with FDA Discussions on Ampligen; Manufacturing Facility for FDA-Approved Alferon N Fully Repaired;...
November 15, 2017 09:45 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV

PHILADELPHIA, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Philadelphia, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D.,...